UPPTHERA Inc is a pharmaceutical venture company aiming for new drug development based on Targeted Protein Degradation.

Targeted Protein Degradation

Paradigm Changer in Drug Development

UPPTHERA is a young venture company developing innovative drugs based on targeted protein degradation technology. This technology addresses various diseases for which suitable biological solutions could not be found through conventional drug therapy methods. It degrades the root causes of diseases, thus aiming to substantially enhance therapeutic effiacy. UPPTHERA is dedicated to research and business development to bring these tools closer to those in need.

New E3L Platform

Powerful Drug Discovery Options

While everyone in the TPD feld recognizes the importance of Novel E3L, opinions vary on what to develop and how to efficiently discover the optimal binder. UPPTHERA has developed a proprietary novel E3L target ID solution called UPPGRADER and a chemoproteomics-based E3L ligand screening platform named UPPBEAT. These robust tools enable UPPTHERA to precisely and accurately identify promising novel E3Ls worth developing and effectively secure their novel ligands. Through these technology platforms, UPPTHERA is advancing the novel E3L platforms & next-generation degraders based on them to tackle therapeutic unmet needs.

Press Release